Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Congenital or acquired deficiency of one of the coagulation factors. It results in bleeding.
No HPO annotations are available for this condition.
Venous thromboembolism (VTE) is the primary clinical manifestation of factor V Leiden thrombophilia . The most common site for VTE is the legs, but upper-extremity, cerebral, and superficial venous thrombosis may also occur. The relative risk for VTE is increased approximately three- to eightfold in factor V Leiden variant heterozygotes . Lower relative risks (four- to fivefold) were reported in two large meta-analyses . Despite the increase in relative risk, the overall annual incidence of a first VTE is low in heterozygotes, approximately 0.5% . The reported adjusted hazard ratio (HR) for VTE in heterozygotes compared with controls was 2.7 (95% confidence interval [CI] 1.8-3.8) .
Factor V Leiden thrombophilia should be suspected in individuals with the following clinical, laboratory, and family history findings:
Clinical findings. A history of one or recurrent venous thromboembolism (VTE) manifesting as deep vein thrombosis (DVT) or pulmonary embolism (PE), especially at a young age and in the absence of strong risk factors for VTE
Laboratory findings. Low activated protein C (APC) resistance on APC resistance qualitative and quantitative assays
No approved treatments are currently available for coagulation protein disease. The disease remains an area of unmet medical need.
Gene therapy approaches for coagulation protein disease have been reported in the published literature.
To assess the risk for venous thromboembolism (VTE) in an individual found to have a factor V Leiden variant, the following are recommended:
Individuals receiving long-term anticoagulation require periodic reevaluation of their clinical course to confirm that the benefits of anticoagulation continue to outweigh the risk of bleeding. Factor V Leiden heterozygotes who do not require long-term anticoagulation may benefit from evaluation prior to exposure to circumstantial risk factors such as surgery or pregnancy.
Source: GeneReviews — "Factor V Leiden Thrombophilia"
2 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE4. Research is primarily sponsored by academic and government institutions.
375 publications have been identified in PubMed for coagulation protein disease. Kisho has analyzed 191 by research type. Research spans Basic Science / Preclinical (38%), Review / Meta-Analysis (30%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 72 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
Source: GeneReviews — "Factor V Leiden Thrombophilia"
Source: GeneReviews — "Factor V Leiden Thrombophilia"
The differential diagnosis of venous thromboembolism (VTE) includes several other inherited thrombophilic disorders, including those caused by other variants in F5, and acquired thrombophilic disorders (outside of the scope of this GeneReview). Prothrombin thrombophilia is characterized by VTE manifesting most commonly in adults as deep vein thrombosis (DVT) in the legs or pulmonary embolism. The clinical expression of prothrombin thrombophilia is variable; many individuals heterozygous or homozygous for the 20210GA F2 variant never develop thrombosis, and while most heterozygotes who develop thrombotic complications remain asymptomatic until adulthood, some have recurrent thromboembolism before age 30 years.
Source: GeneReviews — "Factor V Leiden Thrombophilia"
Biomarker and diagnostic research for coagulation protein disease has been reported in the published literature.
DNA analysis for prothrombin thrombophilia (F2 variant c.*97GA, commonly known as 20210GA)
Multiple phospholipid-dependent coagulation assays for a lupus inhibitor
Serologic assays for anticardiolipin antibodies and anti-beta-2-glycoprotein 1 antibodies
For high-risk individuals (i.e., those with a history of recurrent VTE, especially at a young age, or those with strong family history of VTE at a young age), evaluation should also include assays of:
Protein C activity
Antithrombin activity
Protein S activity or free protein S antigen
Note: Measurement of the following is NOT recommended:
Plasma concentration of homocysteine, as no data support a change in duration of anticoagulation or the use of vitamin supplementation in individuals with hyperhomocysteinemia and a history of VTE
MTHFR variants, as no clinical rationale for this testing exists
Factor VIII and other clotting factor levels
Treatment of Manifestations
The management of individuals with factor V Leiden thrombophilia depends on the clinical circumstances. The first acute thrombosis should be treated according to current guidelines . For initial treatment of VTE, current guidelines suggest a direct oral anticoagulant (dabigatran, edoxaban, rivaroxaban, or apixaban) over warfarin because of a lower bleeding risk and gr...
Source: GeneReviews — "Factor V Leiden Thrombophilia"
2 trials found
38%
Research summaries | 57 | 30% |
Disease patterns and progression | 28 | 15% |
Testing and diagnosis research | 15 | 8% |
Clinical study results | 9 | 5% |
New treatment approaches | 7 | 4% |
Patient case studies | 3 | 2% |
Yindi T (2026). [PMID: 41668355](https://pubmed.ncbi.nlm.nih.gov/41668355/). *Med Sci Monit*. [Clinical Trial Publication]
Shaw JR (2026). [PMID: 42102583](https://pubmed.ncbi.nlm.nih.gov/42102583/). *Pharmacol Rev*. [Review / Meta-Analysis]
Connell NT (2026). [PMID: 41201390](https://pubmed.ncbi.nlm.nih.gov/41201390/). *Blood Adv*. [Review / Meta-Analysis]
Sabater-Lleal M (2026). [PMID: 41352609](https://pubmed.ncbi.nlm.nih.gov/41352609/). *J Thromb Haemost*. [Review / Meta-Analysis]
Schwarz N (2026). [PMID: 40209762](https://pubmed.ncbi.nlm.nih.gov/40209762/). *Thromb Haemost*. [Epidemiology / Natural History]
Vandersmissen H (2026). [PMID: 41084872](https://pubmed.ncbi.nlm.nih.gov/41084872/). *Eur J Anaesthesiol*. [Review / Meta-Analysis]
Sundler Björkman L (2026). [PMID: 41410053](https://pubmed.ncbi.nlm.nih.gov/41410053/). *Arterioscler Thromb Vasc Biol*. [Review / Meta-Analysis]
Prince Eladnani R (2026). [PMID: 41197807](https://pubmed.ncbi.nlm.nih.gov/41197807/). *J Thromb Haemost*. [Review / Meta-Analysis]
Ding Z (2026). [PMID: 40835091](https://pubmed.ncbi.nlm.nih.gov/40835091/). *Clin Chim Acta*. [Diagnostic / Biomarker]
Gao L (2026). [PMID: 42044593](https://pubmed.ncbi.nlm.nih.gov/42044593/). *Phytomedicine*. [Gene Therapy / Novel Therapeutics]